Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial

Fineline Cube May 19, 2025

US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...

Company Drug

China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US

Fineline Cube May 19, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...

Company Drug

FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma

Fineline Cube May 16, 2025

The US Food and Drug Administration (FDA) announced this week an indication extension approval for...

Company Drug

Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease

Fineline Cube May 16, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...

Company Deals

Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership

Fineline Cube May 16, 2025

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...

Company Deals

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products

Fineline Cube May 16, 2025

China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...

Company Medical Device

Beijing Balance Medical’s Renato System Gets NMPA Approval for Valve-in-Valve Therapy

Fineline Cube May 16, 2025

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s...

Company Drug

North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine

Fineline Cube May 16, 2025

China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...

Company Deals

Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss

Fineline Cube May 16, 2025

South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...

Company

Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth

Fineline Cube May 16, 2025

Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY)...

Company Drug

CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine

Fineline Cube May 16, 2025

China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it...

Company Drug

Haisco Pharma’s HSK21542 Approved by NMPA for Post-Abdominal Surgery Pain

Fineline Cube May 16, 2025

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Medical Device

Lifetech Scientific’s Aortic Arch Stent System Approved by China’s NMPA

Fineline Cube May 16, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received marketing approval from...

Company Drug

Sihuan Pharmaceutical’s Bireociclib Approved by NMPA for Advanced Breast Cancer

Fineline Cube May 16, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Drug

CANbridge’s Velaglucerase β Approved by NMPA for Gaucher’s Disease Long-Term Therapy

Fineline Cube May 16, 2025

China-based CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Merck KGaA and JD Health Launch Online Thyroid Care Center in China

Fineline Cube May 16, 2025

The Thyroid Care Center on the JD Health platform, a joint initiative between German pharmaceutical...

Company Drug

Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients

Fineline Cube May 15, 2025

Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...

Company Drug

AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression

Fineline Cube May 15, 2025

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...

Company

BeiGene Announces Plans to Relocate Headquarters to Switzerland from Cayman Islands

Fineline Cube May 15, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology company that has proposed...

Company Drug

Chengdu Kanghong’s KH607 Approved for Clinical Trials in Postpartum Depression

Fineline Cube May 15, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received...

Posts pagination

1 … 213 214 215 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.